Tenax Therapeutics, Inc.
Tenax Therapeutics develops levosimendan, a K-ATP channel activator/calcium sensitizer.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 5Latest story
November 2026
October 2026
August 2026
July 2026
June 2026
Tenax Therapeutics develops levosimendan, a K-ATP channel activator/calcium sensitizer.
November 2026
October 2026
August 2026
July 2026
June 2026